Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

MS Braun; F Adab; C Bradley; K McAdam; G Thomas; NJ Wadd; Daniel Rea; R Philips; C Twelves; J Bozzino; C MacMillan; MP Saunders; R Counsell; H Anderson; A McDonald; J Stewart; A Robinson; S Davies; FJ Richards; MT Seymour

doi:10.1038/sj.bjc.6601237

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

MS Braun, F Adab, C Bradley, K McAdam, G Thomas, NJ Wadd, Daniel Rea, R Philips, C Twelves, J Bozzino, C MacMillan, MP Saunders, R Counsell, H Anderson, A McDonald, J Stewart, A Robinson, S Davies, FJ Richards, MT Seymour

Cancer Clinical Trials Unit

Research output: Contribution to journal › Article

11 Citations (Scopus)

Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

Original language	English
Pages (from-to)	1155-1158
Number of pages	4
Journal	British Journal of Cancer
Volume	89
Issue number	7
DOIs	https://doi.org/10.1038/sj.bjc.6601237
Publication status	Published - 6 Oct 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6601237

Cite this

Braun, MS., Adab, F., Bradley, C., McAdam, K., Thomas, G., Wadd, NJ., Rea, D., Philips, R., Twelves, C., Bozzino, J., MacMillan, C., Saunders, MP., Counsell, R., Anderson, H., McDonald, A., Stewart, J., Robinson, A., Davies, S., Richards, FJ., & Seymour, MT. (2003). Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. British Journal of Cancer, 89(7), 1155-1158. https://doi.org/10.1038/sj.bjc.6601237

@article{16058935b04f4881866f61dcc0bffbcb,

title = "Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer",

abstract = "We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.",

author = "MS Braun and F Adab and C Bradley and K McAdam and G Thomas and NJ Wadd and Daniel Rea and R Philips and C Twelves and J Bozzino and C MacMillan and MP Saunders and R Counsell and H Anderson and A McDonald and J Stewart and A Robinson and S Davies and FJ Richards and MT Seymour",

year = "2003",

month = oct,

day = "6",

doi = "10.1038/sj.bjc.6601237",

language = "English",

volume = "89",

pages = "1155--1158",

journal = "British Journal of Cancer",

publisher = "Cancer Research UK",

number = "7",

}

Braun, MS, Adab, F, Bradley, C, McAdam, K, Thomas, G, Wadd, NJ, Rea, D, Philips, R, Twelves, C, Bozzino, J, MacMillan, C, Saunders, MP, Counsell, R, Anderson, H, McDonald, A, Stewart, J, Robinson, A, Davies, S, Richards, FJ & Seymour, MT 2003, 'Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer', British Journal of Cancer, vol. 89, no. 7, pp. 1155-1158. https://doi.org/10.1038/sj.bjc.6601237

TY - JOUR

T1 - Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

AU - Braun, MS

AU - Adab, F

AU - Bradley, C

AU - McAdam, K

AU - Thomas, G

AU - Wadd, NJ

AU - Rea, Daniel

AU - Philips, R

AU - Twelves, C

AU - Bozzino, J

AU - MacMillan, C

AU - Saunders, MP

AU - Counsell, R

AU - Anderson, H

AU - McDonald, A

AU - Stewart, J

AU - Robinson, A

AU - Davies, S

AU - Richards, FJ

AU - Seymour, MT

PY - 2003/10/6

Y1 - 2003/10/6

N2 - We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

AB - We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

UR - http://www.scopus.com/inward/record.url?scp=0242266500&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601237

DO - 10.1038/sj.bjc.6601237

M3 - Article

C2 - 14520437

VL - 89

SP - 1155

EP - 1158

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this